Opaleye Management’s Cymabay Therapeutics CBAY Stock Holding History

Opaleye Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-566,700	Closed	-$6.21M	–	53
2023 Q2	$6.21M	Buy	+566,700	New	+$5.28M	1.48%	18
2021 Q4	–	Sell	-115,015	Closed	-$420K	–	50
2021 Q3	$420K	Buy	+115,015	New	+$453K	0.08%	47
2019 Q4	–	Sell	-140,000	Closed	-$717K	–	53
2019 Q3	$717K	Buy	+140,000	New	+$848K	0.26%	45
2019 Q2	–	Sell	-550,000	Closed	-$7.3M	–	55
2019 Q1	$7.3M	Sell	550,000 -175,000	-24%	-$1.86M	2.02%	21
2018 Q4	$5.71M	Buy	725,000 +26,900	+4%	+$256K	2.13%	17
2018 Q3	$7.74M	Buy	698,100 +600	+0.1%	+$7.45K	1.97%	19
2018 Q2	$9.36M	Buy	697,500 +32,500	+5%	+$407K	2.42%	12
2018 Q1	$8.64M	Hold	665,000	–	–	2.47%	11
2017 Q4	$6.12M	Hold	665,000	–	–	1.96%	16
2017 Q3	$5.36M	Buy	+665,000	New	+$4.5M	1.89%	18

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Opaleye Management's CBAY Position: Q3 2023 in Review

Opaleye Management sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 566,700 shares — an estimated $6.21M sold.

Opaleye Management first reported a position in CBAY in Q3 2017 and held it in 10 quarters. The position peaked at $9.36M in Q2 2018. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

Opaleye Management reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
Opaleye Management sold 566,700 Cymabay Therapeutics shares in Q3 2023, an estimated $6.21M.
Opaleye Management first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 10 quarters.
Opaleye Management's Cymabay Therapeutics position peaked at $9.36M in Q2 2018.
189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.